Severe cutaneous adverse reactions associated with immune checkpoint inhibitors therapy and anti-VEGF combination therapy: a real-world study of the FDA adverse event reporting system

References

• Li JY, Chen YP, Li YQ, et al. Chemotherapeutic and targeted agents can modulate the tumor microenvironment and increase the efficacy of immune checkpoint blockades. Mol Cancer. 2021;20(1):27. doi: 10.1186/s12943-021-01317-7
   PubMed Web of Science ®Google Scholar
• Casak SJ, Marcus L, Fashoyin-Aje L, et al. FDA Approval summary: pembrolizumab for the first-line treatment of patients with MSI-H/dMMR Advanced unresectable or metastatic colorectal carcinoma. Clin Cancer Res. 2021;27(17):4680–4684. doi: 10.1158/1078-0432.CCR-21-0557
   PubMed Web of Science ®Google Scholar
• Fashoyin-Aje L, Donoghue M, Chen H, et al. FDA approval summary: pembrolizumab for recurrent locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma expressing PD-L1. Oncology. 2019;24(1):103–109. doi: 10.1634/theoncologist.2018-0221
   Google Scholar
• Pai-Scherf L, Blumenthal GM, Li H, et al. FDA approval summary: pembrolizumab for treatment of metastatic non-small cell lung cancer: first-line therapy and beyond. Oncology. 2017;22(11):1392–1399. doi: 10.1634/theoncologist.2017-0078
   Google Scholar
• Beaver JA, Theoret MR, Mushti S, et al. FDA approval of nivolumab for the first-line treatment of patients with BRAFV600 wild-type unresectable or metastatic melanoma. Clin Cancer Res. 2017;23(14):3479–3483. doi: 10.1158/1078-0432.CCR-16-0714
   PubMed Web of Science ®Google Scholar
• Upadhaya S, Neftelino ST, Hodge JP, et al. Combinations take centre stage in PD1/PDL1 inhibitor clinical trials. Nat Rev Drug Discov. 2021;20(3):168–169. doi: 10.1038/d41573-020-00204-y
   PubMed Web of Science ®Google Scholar
• Datta M, Coussens LM, Nishikawa H, et al. Reprogramming the tumor microenvironment to improve immunotherapy: emerging strategies and combination therapies. Am Soc Clin Oncol Educ Book. 2019;39(39):165–174. doi: 10.1200/EDBK_237987
   PubMedGoogle Scholar
• Shigeta K, Datta M, Hato T, et al. Dual programmed death receptor-1 and vascular endothelial growth factor receptor-2 blockade promotes vascular normalization and enhances antitumor immune responses in hepatocellular carcinoma. Hepatology. 2020;71(4):1247–1261. doi: 10.1002/hep.30889
   PubMed Web of Science ®Google Scholar
• Lee MS, Ryoo BY, Hsu CH, et al. Lee KH atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): an open-label, multicentre, phase 1b study. Lancet Oncol. 2020;21(6):808–820. doi: 10.1016/S1470-2045(20)30156-X
   PubMed Web of Science ®Google Scholar
• Socinski MA, Mok TS, Nishio M. Abstract CT216: IMpower150 final analysis: efficacy of atezolizumab (atezo) + bevacizumab (bev) and chemotherapy in first-line (1L) metastatic nonsquamous (nsq) non-small cell lung cancer (NSCLC) across key subgroups. Cancer Res. 2020;80(16_Supplement):CT216–CT216. doi: 10.1158/1538-7445.AM2020-CT216
   Google Scholar
• Herbst RS, Arkenau HT, Bendell J, et al. Phase 1 expansion cohort of ramucirumab plus pembrolizumab in advanced treatment-naive NSCLC. J Thorac Oncol. 2021;16(2):289–298. doi: 10.1016/j.jtho.2020.10.004
   PubMed Web of Science ®Google Scholar
• Kennedy LB, Salama AKS. A review of cancer immunotherapy toxicity. CA A Cancer J Clin. 2020;70(2):86–104. doi: 10.3322/caac.21596
   PubMed Web of Science ®Google Scholar
• Chen DS, Mellmanm I. Oncology meets immunology: the cancer-immunity cycle. Immunity. 2013;39(1):1–10. doi: 10.1016/j.immuni.2013.07.012
   PubMed Web of Science ®Google Scholar
• Iyer PG, Albini TA. Drug-related adverse effects of antivascular endothelial growth factor agents. Curr Opin Ophthalmol. 2021;32(3):191–197. doi: 10.1097/ICU.0000000000000757
   PubMed Web of Science ®Google Scholar
• Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012;366(26):2443–2454. doi: 10.1056/NEJMoa1200690
   PubMed Web of Science ®Google Scholar
• Nishino M, Sholl LM, Hodi FS, et al. Anti-PD-1-Related pneumonitis during cancer immunotherapy. N Engl J Med. 2015;373(3):288–290. doi: 10.1056/NEJMc1505197
   PubMed Web of Science ®Google Scholar
• Roujeau JC, Stern RS. Severe adverse cutaneous reactions to drugs. N Engl J Med. 1994;331(19):1272–1285. doi: 10.1056/NEJM199411103311906
   PubMed Web of Science ®Google Scholar
• Muntyanu A, Netchiporouk E, Gerstein W, et al. Cutaneous immune-related adverse events (irAes) to immune checkpoint inhibitors: a dermatology perspective on management. J Cutan Med Surg. 2021;25(1):59–76. doi: 10.1177/1203475420943260
   PubMed Web of Science ®Google Scholar
• Yang MS, Lee JY, Kim J, et al. Incidence of Stevens-Johnson syndrome and toxic epidermal necrolysis: a nationwide population-based study using national health insurance database in Korea. PLoS One. 2015;11(11):e0165933. doi: 10.1371/journal.pone.0165933
   Web of Science ®Google Scholar
• Schaerli P, Britschgi M, Keller M, et al. Characterization of human T cells that regulate neutrophilic skin inflammation. J Immunol. 2004;173(3):2151–2158. doi: 10.4049/jimmunol.173.3.2151
   PubMed Web of Science ®Google Scholar
• Knowles SR, Shapiro LE, Shear NH. Anticonvulsant hypersensitivity syndrome: incidence, prevention and management. Drug Saf. 1999;21(6):489–501. doi: 10.2165/00002018-199921060-00005
   PubMed Web of Science ®Google Scholar
• Dodiuk-GAD RP, Laws PM, Shear NH. Epidemiology of severe cutaneous drug hypersensitivity. Semin Cutan Med Surg. 2014;33(1):2–9. doi: 10.12788/j.sder.0057
   PubMed Web of Science ®Google Scholar
• Phillips GS, Wu J, Hellmann MD, et al. Treatment outcomes of immune-related cutaneous adverse events. J Clin Oncol. 2019;37(30):2746–2758. doi: 10.1200/JCO.18.02141
   PubMed Web of Science ®Google Scholar
• Maloney NJ, Ravi V, Cheng K, et al. Stevens-Johnson syndrome and toxic epidermal necrolysis-like reactions to checkpoint inhibitors: a systematic review. Int J Dermatol. 2020;59(6):e183–e188. doi: 10.1111/ijd.14811
   PubMed Web of Science ®Google Scholar
• Zhang P, Lao D, Chen H, et al. Neuromuscular junction dysfunctions due to immune checkpoint inhibitors therapy: an analysis of FAERS data in the past 15 years. Front Immunol. 2022;13:778635. doi: 10.3389/fimmu.2022.778635
   PubMedGoogle Scholar
• Van Puijenbroek EP, Bate A, Leufkens HG, et al. A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions. Pharmacoepidemiol Drug Saf. 2002;11(1):3–10. doi: 10.1002/pds.668
   PubMed Web of Science ®Google Scholar
• Szumilas M. Explaining odds ratios. J Can Acad Child Adolesc Psych. 2010;19(3):227–229.
   PubMed Web of Science ®Google Scholar
• Ooba N, Kubota K. Selected control events and reporting odds ratio in signal detection methodology. Pharmacoepidemiol Drug Saf. 2010;19(11):1159–1165. doi: 10.1002/pds.2014
   PubMed Web of Science ®Google Scholar
• Evans SJ, Waller PC, Davis S. Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports. Pharmacoepidemiol Drug Saf. 2001;10(6):483–486. doi: 10.1002/pds.677
   PubMed Web of Science ®Google Scholar
• Hauben M, Madigan D, Gerrits CM, et al. The role of data mining in pharmacovigilance. Expert Opin Drug Saf. 2005;4(5):929–948. doi: 10.1517/14740338.4.5.929
   PubMedGoogle Scholar
• Dumouchel W. Bayesian data mining in large frequency tables, with an application to the FDA spontaneous reporting system. Am Statistician. 1999;53(3):177–190. doi: 10.1080/00031305.1999.10474456
   Web of Science ®Google Scholar
• Szarfman A, Machado SG, O’neill RT. Use of screening algorithms and computer systems to efficiently signal higher-than-expected combinations of drugs and events in the US FDA’s spontaneous reports database. Drug Saf. 2002;25(6):381–392. doi: 10.2165/00002018-200225060-00001
   PubMed Web of Science ®Google Scholar
• Sibaud V. Dermatologic reactions to immune checkpoint inhibitors: skin toxicities and immunotherapy. Am J Clin Dermatol. 2018;19(3):345–361. doi: 10.1007/s40257-017-0336-3
   PubMed Web of Science ®Google Scholar
• Zhu J, Chen G, He Z, et al. Stevens-Johnson syndrome/toxic epidermal necrolysis in patients treated with immune checkpoint inhibitors: a safety analysis of clinical trials and FDA pharmacovigilance database. EClinicalMedicine. 2021;37:100951. doi: 10.1016/j.eclinm.2021.100951
   PubMedGoogle Scholar
• Khoja L, Day D, Chen TWW, et al. Tumour- and class-specific patterns of immune-related adverse events of immune checkpoint inhibitors: a systematic review. Ann Oncol. 2017;28(10):2377–2385. doi: 10.1093/annonc/mdx286
   PubMed Web of Science ®Google Scholar
• Goldinger SM, Stieger P, Meier B, et al. Cytotoxic cutaneous adverse drug reactions during anti-PD-1 therapy. Clin Cancer Res. 2016;22(16):4023–4029. doi: 10.1158/1078-0432.CCR-15-2872
   PubMed Web of Science ®Google Scholar
• Mustafa SS, Ostrov D, Yerly D. Severe cutaneous adverse drug reactions: presentation, risk factors, and management. Curr Allergy Asthma Rep. 2018;18(4):26. doi: 10.1007/s11882-018-0778-6
   PubMed Web of Science ®Google Scholar
• Kardaun SH, Sekula P, Valeyrie- Allanore L, et al. RegiSCAR study group, drug reaction with eosinophilia and systemic symptoms (DRESS): an original multisystem adverse drug reaction. Results From The Prospective RegiScar Study, Br J Dermatol. 2013;169(5):1071–1080. doi:10.1111/bjd.12501
   Google Scholar
• Sassolas B, Haddad C, Mockenhaupt M, et al. ALDEN, an algorithm for assessment of drug causality in Stevens–Johnson syndrome and toxic epidermal necrolysis: comparison with case-control analysis. Clin Pharmacol Ther. 2010;88(1):60–68. doi: 10.1038/clpt.2009.252
   PubMed Web of Science ®Google Scholar
• Saw S, Lee HY, Ng QS. Pembrolizumab-induced Stevens-Johnson syndrome in non-melanoma patients. Eur J Cancer. 2017;81:237–239. doi: 10.1016/j.ejca.2017.03.026
   PubMed Web of Science ®Google Scholar
• Vivar KL, Deschaine M, Messina J, et al. Epidermal programmed cell death-ligand 1 expression in TEN associated with nivolumab therapy. J Cutan Pathol. 2017;44(4):381–384. doi: 10.1111/cup.12876
   PubMed Web of Science ®Google Scholar
• Apalla Z, Papageorgiou C, Lallas A, et al. Cutaneous adverse events of immune checkpoint inhibitors: a literature review. Dermatol Pract Concept. 2021;11(1):e2021155. doi: 10.5826/dpc.1101a155
   PubMedGoogle Scholar
• Zhu J, Wu J, Li G, et al. Meta-analysis of randomized controlled trials for the incidence and risk of fatal adverse events in cancer patients treated with ipilimumab. Expert Opin Drug Saf. 2017;16(4):423–428. doi: 10.1080/14740338.2017.1297420
   PubMed Web of Science ®Google Scholar
• Lindquist M, Ståhl M, Bate A, et al. A retrospective evaluation of a data mining approach to aid finding new adverse drug reaction signals in the WHO international database. Drug Saf. 2000;23(6):533–542. doi: 10.2165/00002018-200023060-00004
   PubMed Web of Science ®Google Scholar
• Sakaeda T, Tamon A, Kadoyama K, et al. Data mining of the public version of the FDA adverse event reporting system. Int J Med Sci. 2013;10(7):796–803. doi: 10.7150/ijms.6048
   PubMed Web of Science ®Google Scholar
• Caster O, Aoki Y, Gattepaille LM, et al. Disproportionality analysis for pharmacovigilance signal detection in small databases or subsets: recommendations for limiting false-positive associations. Drug Saf. 2020;43(5):479–487. doi: 10.1007/s40264-020-00911-w
   PubMed Web of Science ®Google Scholar